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Abstract
Objective: The increased risk for thrombosis is known as hypercoagulability or thrombophilia. In our study, 
we aimed to determine the frequency of the identified defects for thrombophilia in patients with central 
venous thrombosis aged under 50 years and to compare results with the findings in the current literature. 
Materials and Methods: Forty-three patients (16-50 years old) were retrospectively evaluated. 
Thrombophilia investigation included determinations of protein C, protein S, antithrombin, and acti-
vated protein C resistance, factor V Leiden (FVL), prothrombin 20210A (PT 20210) and methylene 
tetrahydrofolate reductase (MTHFR) C677T mutations, antiphospholipid antibodies (APA), factor 
VIII levels, and homocysteine levels. 
Results: We detected a single thrombophilic defect in 67.4%, two defects in 27.9% and three defects 
in 4.7% of our patients. The most common thrombophilic defect was mutation in the MTHFR gene 
(41.8%), and this was followed by the FVL mutation (34.9%).
Conclusion: Since the prevalence of individual thrombophilic defects varies in each population, ethnic 
group and geographical location, screening for thrombophilic defects in patients presenting with cere-
bral venous thrombosis should primarily investigate the most frequent thrombophilia risk factors.
(Turk J Hematol 2010; 27: 162-7)
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Özet
Amaç: Tromboz riskinin artması hiperkoagulabilite ya da trombofili olarak bilinmektedir. Çalışmamızda, 
serebral venöz tromboz gelişen ve trombofilik defekt saptanan 50 yaş ve altı hastalarımızda tespit edilen 
trombofilik defektleri, sıklığını değerlendirmek ve literatür bilgileriyle karşılaştırmak amaçlanmıştır. Introduction
Thrombosis is abnormal clot formation in the 
vascular system through the interaction of various 
vascular, cellular and humoral factors. It has been 
long known that alterations in the vascular wall, 
blood flow and blood composition (widely known 
as ‘Virchow’s triad’) cause thrombosis.
The impairment of the delicate balance in the 
hemostatic process due to the deficiency of natural 
anticoagulants or defects in the fibrinolytic pathway 
may result in hypercoagulability [1]. An increased 
risk for thrombosis is known as hypercoagulability 
or thrombophilia. Generally, thrombophilia is the 
general term covering a range of hereditary or 
acquired conditions [2]. Currently, arterial and 
venous thrombosis are among the most common 
causes of morbidity and mortality [3].
In random patient populations, thrombophilic 
factors leading to a predisposition to thrombosis 
can be detected in approximately one-third of 
patients with venous thromboembolism. Hereditary 
thrombophilia is detected in more than half of the 
patients in whom thrombophilic defects are pres-
ent. The risk for thrombosis increases in the pres-
ence of multiple thrombophilic defects [3]. 
Hereditary thrombophilic factors and their frequen-
cies exhibit some variations in different populations 
or patient groups [4-8]. Ischemic stroke (IS) is usu-
ally associated with arterial diseases (e.g. carotid 
stenosis) or heart diseases (e.g. atrial fibrillation). In 
studies assessing the role of hereditary thrombo-
philia in the etiology of cerebral arterial and cere-
bral venous thrombosis (CAT, CVT), the risk for 
stroke was found to increase in the presence of dif-
ferent thrombophilic factors [9-16]. Hypercoagulable 
states are responsible for 5-10% of all IS cases, and 
hereditary thrombophilia is especially more com-
mon in the etiology of IS in the younger subgroup of 
patients [17]. 
In the present study, we aimed to assess the fre-
quency of the identified defects for thrombophilia in 
patients with CVT and thrombophilic defects aged 
≤50 years and to compare our data with the reports 
in the literature.
Materials and Methods
Patients
Forty-three patients (30 females, 13 males; medi-
an age: 36 years; range: 16-50) with CVT and throm-
bophilic defects aged ≤50 years were included in 
the study. All subjects were diagnosed to have CVT 
by the neurology clinics, and each patient was con-
sulted with the hematology clinic to explore the 
etiology of the underlying thrombophilic factor. CVT 
was diagnosed by means of magnetic resonance 
imaging (MRI). Chronic liver diseases, diabetes mel-
litus, dyslipidemia, presence of central venous cath-
eter, history of recent surgical procedures, myelo-
proliferative diseases, paroxysmal nocturnal hemo-
globinuria, malignancies, autoimmune diseases, 
hormone replacement therapy, and oral contracep-
tive usage were the exclusion criteria. Laboratory 
tests were performed under the following condi-
tions: 15 days after discontinuation of heparin or its 
derivatives, four weeks after discontinuation of cou-
madin derivatives, and three months later in patients 
with a history of thrombosis. The tests were repeat-
ed in the event of positive results. Oral informed 
consent were obtained from all patients.
Assessments
Antithrombin (AT) activity, protein C (PC) activity, 
total and free protein S (PS) antigen and activity, 
activated protein C resistance (APC-R), factor V 
Leiden (FVL) G1691A, prothrombin 20210A (PT 
20210), and methylene tetrahydrofolate reductase 
(MTHFR) C677T mutations, factor VIII (FVIII) levels, 
fasting homocysteine levels, and antiphospholipid 
Yöntem ve Gereçler: 16-50 yaş arasında 43 hasta retrospektif olarak değerlendirildi. Trombofili tet-
kiki olarak protein C, protein S, antitrombin eksikliği, aktive protein C rezistansı, faktör V Leiden 
(FVL), protrombin 20210A (PT 20210), metilentetrahidrofolat redüktaz (MTHFR) gen mutasyonları, 
antifosfolipid antikorları (AFA), faktör VIII ve homosistein yüksekliği araştırıldı. 
Bulgular: Hastalarımızın %67.4’ünde tek, %27.9’unda iki, %4.7’sinde üç trombofilik defekt saptadık. 
En sık saptanan defekt MTHFR gen mutasyonu (%41.8) idi, bunu FVL mutasyonu (%34.9) takip etti. 
Sonuç: Trombofili etkenlerinin sıklığı, etnik farklılık ve coğrafi bölgelere göre değişebildiğinden, her 
toplum serebral venöz tromboz kliniği ile başvuran hastalarda öncelikle sık görülen trombofili etken-
lerini araştırmalıdır. (Turk J Hematol 2010; 27: 162-7)
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IgG and ACA IgM, and lupus anticoagulant [LA]) 
were assessed in our study. MTHFR C677T muta-
tions were assessed by commercial polymerase 
chain reaction (PCR) kits (MTHFR LC PCR, QIAGEN). 
Factor II (prothrombin) G20210A and FVL mutations 
were determined by commercial kits (Roche 
Diagnostics). “LightCycler 1.5 Roche” real-time PCR 
device was used in this study. AT, PC, PS, APC-R, LA, 
and FVIII levels were assessed in citrated peripheric 
blood samples drawn after a 12-hour fast, which 
were centrifuged at 1500 x g for 15 minutes. Citrated 
samples were stored at -20°C until testing. PC, PS, 
AT and FVIII were studied using commercial kits 
(Dade Behring), and APC-R was determined by a 
Dade Behring proC global kit. These analyses were 
performed on the BCS instrument (Dade Behring). 
Homocysteine levels were evaluated using Recipe 
commercial kits (Recipe Chemical and Instruments 
GmbH, Munich, Germany) by Shimadzu HPLC ana-
lyzer. A laboratory reference range study performed 
with 40 healthy individuals was established to deter-
mine the cut-off value to define PC (70-140%), PS 
(58-127%), AT (75-125%) and FVIII (70-150%) activi-
ty. LA-sensitive activated partial thromboplastin 
time (aPTT) reagent PTT-LA (Diagnostica Stago) 
test was performed for the patients with high levels 
of aPTT. Presence of heparin, intrinsic pathway fac-
tor deficiencies, factor inhibitors, and dysfibrinogen-
emia was ruled out. In the presence of LA, the 
plasma clotting time increases. A difference of 
8 seconds between the two clotting times is thought 
to be positive for LA [18,19]. These analyses were 
performed on the Diagnostica Stago STart® 4 
Hemostasis Analyzer (Diagnostica Stago, France).
ACA IgM and ACA IgG levels were evaluated by 
Intec cardiolipin IgM and IgG commercial ELISA kits 
on a Biomaster instrument. ACA IgM and ACA IgG of 
less than 2.0 PL-U/ml were accepted as normal 
range. The determination of >12 PL-U/ml value in at 
least two separate measurements was considered 
positive. The normal range of homocysteine in plas-
ma/serum was accepted to be between 5.5-14 
μmol/L. A minimum of two determinations of homo-
cysteine level >14 μmol/L was considered as “high”. 
All blood samples were drawn after formal writ-
ten consent was obtained from the patients. The 
study was carried out in accordance with the 
Helsinki Declaration. 
Statistical analysis
SPSS 11.5 for Windows Statistical Software Pack-
age was used to analyze the data. The descriptive 
statistics used for continuous variables were per-
centage (%) and mean±standard deviation for cat-
egorical variables. Fisher’s exact or chi-square test 
was used for categorical comparisons. Statistical 
significance was assigned as p values lower than 
0.05.
Results
Demographical properties of the patients are 
shown in Table 1. A previous thrombotic episode 
was present in 2 patients (4.7%) and a family history 
of a thrombotic episode was observed in 3 patients 
(6.9%). Among all cases, 38 patients (88%) were on 
antithrombotic medication (aspirin, coumadin, and 
low molecular weight heparin, either as single 
agents or in combinations). We detected a single 
thrombophilic defect in 29 (67.4%), two defects in 
12 (27.9%) and three defects in 2 (4.7%) of our 
patients. There was no significant difference 
between male and female patients with regard to 
the presence of a single or combined thrombophilic 
defects (p=0.491). The frequencies of the thrombo-
philic defects that we could detect were as follows: 
The most frequent thrombophilic defect was a 
defect in the MTHFR gene, present in 41.8% (n=18) 
of the patients; 13 of the patients were heterozygote 
and 5 were homozygote. This defect was present as 
a single defect in 50% and as a joint defect with oth-
ers in 50% of our patients. The second most com-
mon thrombophilic defect was FVL mutation, which 
was observed in 34.9% (n=15) of the patients, with 
13 patients being heterozygote and 2 cases homozy-
gote. Other frequent thrombophilic defects were 
the presence of APA and PS deficiency, which were 
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Table 1. Demographic characteristics of the patients
Patients (n)  43
Males (n)  13 (30.2%)
Females (n)  30 (69.8%)
Median age (overall) (years)  36 (16-50)
Median age (females) (years)  35 (16-49)
Median age (males) (years)  37 (20-50)
Previous thrombotic events   2 (4.7%)
Family history of thrombotic events  3 (6.9%)
Antithrombotic medication  38 (88%)observed in 18% (n=8) of the patients. This was fol-
lowed by elevated FVIII and homocysteine levels, 
detected in only 2 patients. Similarly, PC deficiency 
was also detected in 2 patients. AT deficiency was 
in the screening program but was not detected in 
any of our patients. Nine of the patients with a muta-
tion in the MTHFR gene, 6 patients with a FVL muta-
tion and 5 patients with APA had combined throm-
bophilic defects. The most frequent pair of throm-
bophilic defects was the combination of a defect in 
the MTHFR gene + FVL mutation (n=5), followed 
by a defect in the MTHFR gene + APA (9%, n=4). 
The difference in frequencies between male and 
female patients was not statistically significant in 
any of the above-mentioned thrombophilic defects. 
The frequencies of the various thrombophilic 
defects are shown in Tables 2 and 3. Recurrent 
abortus coexisted with CVT in 3 of our patients and 
in 1 CVT patient, retinal artery thrombosis was also 
present. 
Discussion
Thromboembolism manifests itself mostly in 
adults and is a multicausal clinical entity [2]. 
Increasingly more reports in the literature demon-
strate that hereditary defects are as important as 
acquired factors in the etiology of thromboembolic 
disease in adults [5,6,8,20]. However, several issues 
are still under investigation, such as in which popu-
lations, age groups and in the presence of which 
acquired factors will hereditary defects cause a ten-
dency towards clinical thrombosis and which 
combination(s) constitute a strong synergy [21,22]. 
In a study conducted on patients with venous 
thromboembolism [23], thrombophilia was found 
in 41% of the patients, and in 32%, it involved a 
genetic cause. The FVL was found in 15%, followed 
by natural anticoagulant dysfunction (11%). Similar 
to our results, the authors observed that thrombo-
philia frequency did not change significantly with 
age or gender. Hankey et al. [24] performed a case-
control study of 219 hospital cases with a first-ever 
IS and 205 randomly selected community control 
subjects in order to identify the role of hereditary 
thrombophilia in IS. They did not observe significant 
differences in the prevalence of thrombophilia 
between cases and control subjects or between 
pathogenic subtypes of IS. In another case-control 
study reported by Cantu et al. [25], the potential 
association among homocysteine, folate and vita-
min B12 levels and the common C677T mutation in 
the MTHFR gene was examined in patients with 
CVT. The authors also performed thrombophilic 
tests and reported a higher prevalence of APC-R 
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Table 2. Prevalence of hereditary thrombophilic factors and gender 
distribution 
  Males    Females  Total
 (n=13)  (n=30)  (n=43)
   n % n  %  n %
PC   0  0  2  6.7  2  4.7
PS   1  7.7  7  23.3  8  18.6
MTHFR  6 46.2 12  40  18 41.8
PT 20210  2  15.4  2  6.7  4  9.3
FVL  5 38.5 10  33.3  15 34.9
FVIII  1 7.7 1  3.3  2 4.7
APA 1  7.7  7  23.3  8  18.6
Homocysteine    1 7.7 1  3.3  2 4.7
Elevation 
PC: Protein C deficiency; PS: Protein S deficiency; FVL: Factor V Leiden G1691A 
mutation; MTHFR: 5,10-Methylenetetrahydrofolate reductase C677T mutation; 
PT 20210: Prothrombin G20210A mutation; FVIII: Elevated factor VIII levels; APA: 
Antiphospholipid antibody (anticardiolipin antibody IgG, IgM and lupus antico-
agulant)
Table 3. The distribution of single and combined mutations in cases 
of cerebral venous thrombosis
  Single thrombophilic defect: 29 (67.4%)
n=43  Two defects: 12 (27.9%)
  Three defects: 2 (4.7%)
  MTHFR: 41.8 (n=18; 13 heterozygotes,
 5  homozygotes)
Most frequent  FVL: 34.9 (n=15; 13 heterozygotes, 
thrombophilic defects (%)  2 homozygotes)
  APA: 18.6 (n=8)
  Protein S: 18.6 (n=8)
  PT 20210: 9.3 (n=4; 4 heterozygotes)
  Most frequent: 20.9 MTHFR (n=9)
Frequency of the  2nd most frequent: 13.9 FVL (n=6)
combined mutations (%)  and 11.6 APA (n=5)
  MTHFR+FVL: 6.9 (n=3)
  MTHFR+APA: 6.9 (n=3)
 MTHFR+PS,  MTHFR+FVL+PS, 
  MTHFR+FVL+PT 20210, FVL+PS, 
  PS+PT 20210, FVIII+APA, 
 APA+Homocysteine  Elevation: 
 2.3  (n=1) 
PC: Protein C deficiency; PS: Protein S deficiency; FVL: Factor V Leiden G1691A muta-
tion; MTHFR: 5,10-Methylenetetrahydrofolate reductase C677T mutation; PT 20210: 
Prothrombin G20210A mutation; FVIII: Elevated factor VIII levels; APA: Antiphospholipid 
antibody (anticardiolipin antibody IgG, IgM and lupus anticoagulant)and presence of FVL and mutation in the PT gene 
(G20210A) in CVT patients [25]. In another study 
conducted in patients with CVT [26], infections and 
postpartum state were found to be the most com-
mon predisposing factors for CVT, and the preva-
lence of genetic thrombophilia was 5%. In our study, 
CVT did not develop during the gestation or puer-
peral period in female cases. In populations with 
low folate levels and low socioeconomic status, 
mutation in the MTHFR gene and hyperhomocyste-
inemia increase the risk for IS [9,10,15,25]. In a 
study performed on 125 patients by Nadir et al. [27], 
there was no correlation between high plasma 
homocysteine levels and C677T mutation in the 
MTHFR gene. In our study, only two cases among 43 
were determined to have homocysteine levels 
above the normal (14 μmol/L). No MTHFR gene 
mutation was detected in these cases. The fasting 
homocysteine levels of the remaining 41 cases 
were within the normal range.
In the present study, we detected two or more 
thrombophilic defects in 32% of our patients. This 
finding shows that approximately one-third of all 
patients presented with combined thrombophilic 
defects. Thus, the search for these defects should 
not be stopped when one defect is detected; rather 
it would be an appropriate approach to continue 
the scan for at least 3-5 of the most common throm-
bophilic defects. The presence of MTHFR and FVL 
mutations and APA in our patients with CVT was in 
accordance with a study performed on pregnant 
women with venous thromboembolism [28]. 
Similar to our results, in a study performed in 
Australia [29], the MTHFR C677T polymorphism 
was the most common inherited thrombophilic 
defect. In that study, the birth prevalences of hetero-
zygosity and homozygosity for the MTHFR C677T 
polymorphism were 37.3% and 12.4%, respectively. 
The authors concluded that inherited thrombophilic 
polymorphisms are common in the Caucasian 
Australian population, but the reason why thrombo-
embolic disorders are not observed in most of these 
subjects may be the absence of additional risk fac-
tors, which facilitate the clinical manifestation of 
thromboembolism [29]. The association between 
the MTHFR C677T polymorphism and vascular dis-
ease is still a matter of debate [9,10,15,16,30]. The 
high number of polymorphic alleles and the differ-
ential distribution of these polymorphisms among 
various ethnic groups (more prevalent among sub-
jects of Caucasian decent than blacks) are some of 
the factors that make it difficult to comment on the 
results of various studies and to derive general con-
clusions [16].
In conclusion, since the prevalence of individual 
thrombophilic defects varies in different ethnic 
groups and geographical locations, in each popula-
tion, screening for thrombophilic defects in patients 
presenting with CVT should primarily involve the 
most frequent thrombophilia risk factors. Such an 
approach will enable the initiation of prophylactic 
and therapeutic measures in the appropriate cases 
and thus decrease the economic burden for health-
care. Further studies involving larger patient popula-
tions are mandatory for the evaluation of the rele-
vance of our results with current clinical practice.
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